NCT03931447View on ClinicalTrials.gov

A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

February 10, 2020

Study Completion Date

February 10, 2020

Conditions
Healthy
Interventions
BIOLOGICAL

JNJ-72537634

Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.

BIOLOGICAL

Placebo

Participants will receive matching placebo as oral capsule in all cohorts.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03931447 - A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants | Biotech Hunter | Biotech Hunter